August 25, 2026
How to Qualify for Ketamine Treatment
If you’ve tried antidepressant after antidepressant and still feel stuck, you may be wondering whether there’s another path forward. Ketamine-based treatment has become a meaningful option for people whose depression hasn’t responded to standard medications — but it isn’t a first step, and it isn’t right for everyone.
Qualifying comes down to four things: your treatment history, your diagnosis, your medical profile, and whether supervised in-clinic care is workable for your life. This guide walks through each one, including the factors that can rule someone out — so you’ll know before you call whether it’s worth exploring.
At Time for Ketamine, with clinics in Chattanooga, Tennessee and Atlanta, Georgia, we specialize in ketamine-based mental health care delivered in a closely supervised setting. Qualifying starts with a conversation and a thorough evaluation. To find out whether this treatment could be a fit, connect with our team today.
What Ketamine Treatment Actually Is
Ketamine was first developed and approved as an anesthetic. Over the past two decades, researchers found it may also relieve certain hard-to-treat mental health conditions — often far faster than traditional antidepressants, which can take four to eight weeks to show benefit.
Two forms are used in mental health care today, and the difference matters for eligibility:
- Spravato (esketamine) is a nasal spray FDA-approved in 2019 for adults with treatment-resistant depression, and separately approved for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. In January 2025, the FDA expanded the approval so it can be used as a standalone monotherapy. Esketamine is a molecule derived from ketamine, and the research behind it grew out of work at the National Institute of Mental Health and partner institutions.
- IV ketamine is the original ketamine molecule delivered by infusion. It’s used off-label for depression, meaning providers prescribe it based on clinical research and judgment even though it isn’t FDA-approved for that specific purpose. Off-label prescribing is legal and routine across American medicine.
Both are given under medical supervision. Neither is something you take at home.
The Four Things Providers Actually Assess
1. Your Treatment History
Treatment-resistant depression has a working clinical definition: a depressive episode that hasn’t responded adequately to at least two different antidepressant trials at an adequate dose for an adequate duration within the current episode. Both halves of that phrase matter. Two weeks on a low starter dose you stopped because of side effects generally doesn’t count as an adequate trial. Six to eight weeks at a therapeutic dose does.
Bring the specifics to your evaluation: which medications, what doses, how long, and what happened. If you don’t remember, your prescribing provider or pharmacy record can usually reconstruct it.
2. Your Diagnosis
Ketamine-based care is most established for depression. Providers also explore it for other conditions, with varying levels of evidence behind each:
| Condition | Evidence Status |
|---|---|
| Treatment-resistant depression | Strongest — esketamine is FDA-approved for this indication |
| MDD with acute suicidal ideation | FDA-approved indication for esketamine, alongside an oral antidepressant |
| Certain anxiety conditions | Off-label; growing research, less established |
| PTSD | Off-label; active area of study |
| Substance use challenges | Off-label; emerging, best as part of a broader treatment plan |
A qualified provider will be straightforward with you about which category your situation falls into, rather than overselling what the evidence supports.
3. Your Medical Profile
Ketamine therapy affects the body as well as the mind, so a provider will review your cardiovascular history, blood pressure, liver function, current medications, and any history of psychosis or substance use before clearing you. More on what specifically raises concern below.
4. Whether Supervised Care Fits Your Life
This is the practical criterion people overlook. Treatment happens in a clinic, on a schedule, and you cannot drive yourself home afterward. An initial course typically means multiple visits over several weeks. Before you commit, think through transportation, time away from work, and who can be with you.
IV Ketamine vs. Spravato: What You Qualify For May Differ
Part of qualifying is determining which form fits — and the eligibility criteria aren’t identical.
| IV Ketamine | Spravato (Esketamine) | |
|---|---|---|
| Approval status | Off-label for depression | FDA-approved for TRD and for MDD with acute suicidal ideation |
| How it’s given | Intravenous infusion | Nasal spray, self-administered under supervision |
| Setting | Medically supervised clinic | REMS-certified healthcare setting only |
| Monitoring after | Until effects resolve | Minimum 2 hours, then a clinical readiness assessment |
| Insurance | Often out of pocket | More frequently covered |
| Enrollment | Not required | Outpatients must enroll in the Spravato REMS program |
You can read more about IV ketamine infusions and Spravato treatment individually, but the honest answer is that this decision is made with your provider, weighing your diagnosis, your history, and your coverage.
Who May Not Be a Candidate
It helps to separate the factors that firmly rule out treatment from the ones that simply require closer evaluation. Most people worry they fall in the first category when they’re actually in the second.
Absolute contraindications for Spravato, per its FDA prescribing information:
- Aneurysmal vascular disease, including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels, or arteriovenous malformation
- A history of intracerebral hemorrhage
- Known hypersensitivity to esketamine, ketamine, or any component of the formulation
Factors requiring careful evaluation — not automatic disqualification:
- Uncontrolled high blood pressure. Ketamine can temporarily raise blood pressure. Controlled hypertension is often manageable; uncontrolled hypertension usually needs to be addressed first.
- Heart or cardiovascular conditions. These call for review, sometimes with cardiology input.
- Pregnancy or breastfeeding. Ketamine treatment is generally not recommended during pregnancy.
- A history of psychosis or a psychotic disorder. Because ketamine can produce dissociative effects, this warrants a careful discussion.
- A history of substance use. Ketamine has abuse potential, and the FDA’s prescribing information directs providers to evaluate this risk. This is a reason for an honest conversation and a more structured plan — not a reason to avoid seeking help.
- A past negative reaction to ketamine or anesthesia. Important to disclose if it applies.
- Liver impairment or significant untreated medical illness. May affect dosing or suitability.
Spravato is also not approved for anyone under 18.
Having something on this list doesn’t end the conversation. It means your provider weighs it carefully and builds the safest plan around it.
What the Evaluation Actually Involves
Qualifying always begins with a thorough assessment. Here’s what to expect:
- Before your visit, gather your medication history, a list of anything you currently take (including supplements), your diagnoses, and your insurance information.
- During the evaluation, a provider reviews your mental health history and prior treatments, your physical health and cardiovascular status, your current medications and possible interactions, and your goals for treatment. Vital signs including blood pressure are checked. You’ll also be asked about substance use and any history of psychosis — answered honestly, these questions make your care safer, not harder to access.
- Afterward, your provider tells you whether ketamine-based treatment is appropriate, which form makes sense, what a course would look like, and what it would cost. This is a two-way conversation, not a test to pass — and if it isn’t the right fit, a good provider will point you toward options that may serve you better. You can see what to expect from a treatment session before you begin.
Why Supervision Is Part of Qualifying
One of the most important things to understand is that ketamine treatment belongs in a controlled medical setting. This isn’t a medication to use on your own.
Spravato carries an FDA boxed warning covering sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors — and it’s available only through a restricted REMS program. That means it can be administered only in certified healthcare settings, with a provider present and a monitoring period of at least two hours afterward. IV ketamine is likewise given under direct medical supervision.
The upside of all that structure is peace of mind. You receive care in a private space with trained professionals nearby the entire time, in a setting equipped to respond if anything comes up. You can learn more about our clinic and approach anytime.
Frequently Asked Questions
How many antidepressants do I have to try before I qualify for ketamine treatment?
Generally at least two, from different classes, each taken at an adequate dose for an adequate duration — typically six to eight weeks. A brief trial you stopped early because of side effects usually doesn’t count toward that threshold. Your provider makes the final determination.
Can I qualify for ketamine treatment if I’m currently taking an antidepressant?
Usually yes. Spravato was originally approved for use alongside an oral antidepressant, and as of January 2025 it can also be used as monotherapy. Your provider will review all your current medications for interactions.
Does anxiety qualify me for ketamine treatment?
Anxiety is an off-label use, meaning it isn’t an FDA-approved indication. Some providers offer it for anxiety that hasn’t responded to other treatment, particularly when it occurs alongside depression. A provider can explain what the current evidence supports for your situation.
What automatically disqualifies someone from Spravato?
Per the FDA prescribing information, Spravato is contraindicated for people with aneurysmal vascular disease or arteriovenous malformation, a history of intracerebral hemorrhage, or hypersensitivity to esketamine or ketamine. It’s also not approved for patients under 18.
Will a history of substance use disqualify me?
Not automatically. Ketamine has abuse potential, so providers are required to assess this risk — but it’s evaluated case by case and often means a more structured treatment plan rather than a denial. Being upfront helps your provider design the safest approach.
Do I need a referral from my psychiatrist?
Not necessarily. Many clinics accept self-referrals, though records from your current prescriber make the evaluation faster and more accurate. Bring what you have.
How long does the evaluation take, and is it the same day as treatment?
The evaluation is a separate appointment, typically under an hour. Treatment is scheduled afterward, once you’ve been cleared and any insurance authorization is in place.
Can I drive myself home after treatment?
No. Ketamine causes sedation and dissociation, and you’ll need someone to drive you. Being able to arrange transportation is a genuine part of qualifying for supervised treatment.
Find Ketamine Treatment Today
Wondering how to qualify for ketamine treatment is usually a sign you’re ready to try something new after a long, tiring search for relief. You don’t have to figure out the next step alone — and you don’t have to determine your own eligibility from a webpage. That’s what the evaluation is for.
At Time for Ketamine, our team guides you through evaluation and treatment in a safe, supervised environment across our Chattanooga and Atlanta clinics, so you can focus on healing.
Call us now at 855-515-5606, or request your consultation today to find out whether ketamine treatment is right for you.